lerapolturev

Lerapolturev is a recombinant, live attenuated, nonpathogenic oncolytic virus therapy based on the Sabin type 1 oral poliovirus. It has been genetically modified by replacing its internal ribosomal entry site (IRES) with that from human rhinovirus type 2 (HRV2) to enhance safety and antitumor activity. Lerapolturev targets the poliovirus receptor CD155, which is widely expressed in malignant cells of most solid tumors and antigen-presenting cells within the tumor microenvironment. Its mechanism of action includes direct tumor cell killing, activation of antigen-presenting cells leading to T cell priming and systemic anticancer immunity, and amplification of immune response via recall of polio vaccine-specific T cells. The drug activates both innate and adaptive immune responses—particularly through robust release of type I/III interferons via MDA5 pathway activation—and induces polyfunctional CD4+ and CD8+ T cell responses within tumors. Lerapolturev is being developed primarily for recurrent glioblastoma (GBM), high-grade glioma, metastatic melanoma refractory to anti-PD-1 therapy, bladder cancer (including non-muscle invasive forms), hormone-positive breast cancer, anaplastic astrocytoma/oligodendroglioma/oligoastrocytoma/pleomorphic xanthoastrocytoma, ependymoma, urothelial carcinoma as well as other solid tumors. It has received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA for recurrent glioblastoma; Fast Track status for refractory melanoma[1][3][4][5][6][7].

Other names

oncolytic polio/rhinovirus recombinantnon-neurovirulent rhinovirus:poliovirus chimera